Ray Elliott, the incoming CEO of Boston Scientific, has his work cut out for him.
Elliott would like the company to push into new markets, such as urology, gynecology and women’s health. But the Natick device maker is awash in debt, which Elliott must finish bailing out before making any large strategic moves.
Wall Street analysts are divided over the company’s prospects, Reuters reported, as shares hover just under 8-month-highs (closing at $9.86 July 2).